Table 1.
Baseline demographics
| All subjects (n = 23) | Low dose (n = 13) | High dose (n = 10) | |
|---|---|---|---|
| Age in years (median; IQR) | 40.5 (28.0–44.0) | 35.0 (25.0–46.5) | 41.0 (33.0–44.0) |
| Sex (M to F) | 8:15 | 6:7 | 2:8 |
| Disease (AAV to BD) | 12:11 | 6:7 | 6:4 |
| GPA | 8 | 4 | 4 |
| MPA | 1 | 1 | 0 |
| EGPA | 3 | 1 | 2 |
| BD | 11 | 7 | 4 |
| BVAS/WG score at entry (median; IQR) | 4.0 (4.0–5.5) | 4.0 (4.0–6.0) | 4.5 (4.0–5.0) |
| Prior disease duration in months (median; IQR) | 61.0 (42.0–102.5) | 76.0 (52.0–115.0) | 51.0 (40.0–68.5) |
| Number of previous treatments received (median; IQR) | 4 (3–5) | 5 (3–5) | 4(3–4.75) |
| ANCA specificity (PR3:MPO:Neg) | 7:1:15 | 4:1:8 | 3:0:7 |
| Prior median cumulative cyclophosphamide dose (AAV only) in grams (n = 12) | 9.1 (7–19.4) | 6.4 (4.2–25.8) | 9.6 (8.7–17.3) |
| Prior median cumulative rituximab dose (AAV only) in grams (n = 12) | 4.5 (3–5.75) | 5 (3–6) | 4 (3–5) |
AAV ANCA-associated vasculitis, BD Behçet’s disease, GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis, eGPA eosinophilic granulomatosis with polyangiitis, IQR interquartile range, BVAS/WG Birmingham Vasculitis Activity Score for Wegener’s granulomatosis, PR3 proteinase 3, MPO myeloperoxidase